Imipenem/Cilastatin/Relebactam ( DrugBank: Cilastatin, Imipenem, Relebactam )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 299 | Cystic fibrosis | 1 |
299. Cystic fibrosis
Clinical trials : 1,695 / Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05561764 (ClinicalTrials.gov) | January 3, 2023 | 27/9/2022 | Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis | A Multicenter, Open-label Study to Determine the Pharmacokinetics, Safety, and Outcomes of Imipenem/Cilastatin/Relebactam During Treatment of Acute Pulmonary Exacerbations in Adolescent and Adult Patients With Cystic Fibrosis | Cystic Fibrosis;Pneumonia, Bacterial | Drug: Imipenem/Cilastatin/Relebactam | Hartford Hospital | Merck Sharp & Dohme LLC;Q2 Solutions;Connecticut Children's Medical Center;St. Christopher's Hospital for Children;University of Texas Southwestern Medical Center;University of Pittsburgh Medical Center;Indiana University Health Methodist Hospital;James Whitcomb Riley Hospital for Children | Recruiting | 12 Years | N/A | All | 16 | Phase 4 | United States |